Biomerica Appoints Scott Madel as Chief Commercial Officer to Boost inFoods IBS Commercialization

Biomerica Inc. has appointed Scott Madel as Chief Commercial Officer to accelerate the commercialization of its flagship product, inFoods® IBS. Madel has over 20 years of experience in healthcare and diagnostics, having led Genova Diagnostics to over $100M in revenue. He will focus on strategic partnerships, payer strategy, third-party reimbursement, and expanding provider engagement to boost revenue growth and market expansion.

Biomerica Inc. (NASDAQ: BMRA), a leading biomedical technology company focused on innovative gastroenterology solutions, has appointed Scott Madel as Chief Commercial Officer (CCO) to drive the commercialization of its flagship product, inFoods® IBS. Madel brings over two decades of experience in healthcare and diagnostics, including successful leadership roles at Boston Heart Diagnostics and Genova Diagnostics. His appointment aims to accelerate revenue growth and market expansion for Biomerica's innovative solutions.

Madel's extensive background includes leading organizational turnarounds and growing Genova Diagnostics to over $100 million in annual revenue. Prior to his role at Boston Heart Diagnostics, he served as CEO of BioHealth Diagnostics and Genova Diagnostics Europe. His tenure at Genova Diagnostics involved launching diagnostics for chronic diseases, establishing strategic partnerships across 45 countries, and turning around an accredited European clinical laboratory.

In his new role as CCO, Madel will focus on strategic partnerships, payer strategy, achieving third-party reimbursement, and expanding provider engagement for inFoods® IBS. His appointment signals Biomerica's intensified commercialization push for the innovative diagnostic-guided therapy, which identifies patient-specific food triggers responsible for symptoms such as abdominal pain, bloating, diarrhea, and constipation.

inFoods® IBS is a Laboratory Developed Test (LDT) used within a single laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing. A multicenter, double-blinded placebo-controlled clinical study published in Gastroenterology demonstrated statistically significant outcomes, highlighting inFoods® IBS as the only targeted therapy to show efficacy specifically in IBS-M patients, a subgroup historically underserved by existing treatments.

Biomerica's appointment of Scott Madel as Chief Commercial Officer underscores the company's commitment to leveraging proven revenue growth expertise in diagnostics to drive the success of inFoods® IBS. This strategic move is expected to enhance Biomerica's ability to bring clinically proven breakthrough technology to practitioners and patients worldwide, delivering better outcomes and improving patient experience.

References:
[1] https://www.globenewswire.com/news-release/2025/06/26/3105827/0/en/Clinical-Diagnostics-Industry-Leader-Scott-Madel-Joins-Biomerica-s-Team-as-Chief-Commercial-Officer.html
[2] https://www.stocktitan.net/news/BMRA/clinical-diagnostics-industry-leader-scott-madel-joins-biomerica-s-z12r753n2zxo.html